Related Experiment Video

Updated: Jun 4, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?

N Martelli1, O Mathieu, G Margueritte

  • 1Medical Pharmacology and Toxicology Department, Lapeyronie Hospital, University Hospital of Montpellier, Montpellier, France.

Journal of Clinical Pharmacy and Therapeutics
|March 4, 2011
PubMed

Insights

High-dose methotrexate pharmacokinetics did not significantly impact event-free survival in children with acute lymphoblastic leukemia (ALL). Prognostic factors, not drug levels, were key predictors of relapse in ALL patients.

Area of Science:

  • Pediatric Oncology
  • Pharmacokinetics
  • Hematology

Background:

  • Acute lymphoblastic leukemia (ALL) is the most common childhood cancer in industrialized nations.
  • High-dose methotrexate (MTX) is a standard chemotherapy agent for pediatric ALL.
  • Understanding MTX pharmacokinetics is crucial for optimizing treatment outcomes.

Purpose of the Study:

  • To retrospectively analyze the relationship between high-dose methotrexate pharmacokinetics and event-free survival (EFS) in children with ALL.
  • To compare MTX serum concentrations and pharmacokinetic parameters between children who relapsed and those who remained in EFS.

Main Methods:

  • Retrospective analysis of 69 children with ALL treated with high-dose MTX.
  • Comparison of MTX serum concentrations at 24, 36, 48, and 72 hours post-infusion.
  • Estimation of MTX clearance (Cl), area under the curve (AUC), and volume of distribution (Vd) using NONMEM.

Main Results:

  • No significant differences in MTX pharmacokinetic parameters were observed between relapsed and EFS groups.
  • Known prognostic factors for ALL relapse were significantly associated with relapse in the studied cohort.
  • The study cohort was representative of the general pediatric ALL population.

Conclusions:

  • MTX serum concentrations and pharmacokinetic parameters are not independently associated with treatment outcomes in pediatric ALL.
  • Relying solely on single-drug pharmacokinetic estimates in multi-agent protocols may be unreliable for predicting ALL prognosis.
  • Therapeutic drug monitoring of high-dose MTX is valuable for detecting toxicity and managing drug elimination.
Abstract

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...